Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2012 Feb;100(4):656-64.
doi: 10.1016/j.pbb.2011.08.008. Epub 2011 Aug 26.

Overview of glutamatergic neurotransmission in the nervous system

Affiliations
Review

Overview of glutamatergic neurotransmission in the nervous system

Mark J Niciu et al. Pharmacol Biochem Behav. 2012 Feb.

Abstract

This introductory article to the special edition on glutamate neurotransmission in neuropsychiatric disorders provides an overview of glutamate neurotransmitter system physiology and pharmacology. Glutamate was only relatively recently recognized as the major excitatory neurotransmitter in the mammalian brain, in part due to its ubiquitous nature and diverse metabolic roles within the CNS. The extremely high concentration of glutamate in brain tissue paired with its excitotoxic potential requires tight physiological regulation of extracellular glutamate levels and receptor signaling in order to assure optimal excitatory neurotransmission but limits excitotoxic damage. In order to achieve this high level of control, the system has developed a complex physiology with multiple regulatory processes modulating glutamate metabolism, release, receptor signaling, and uptake. The basic physiology of the various regulatory components of the system including the rich receptor pharmacology is briefly reviewed. Potential contributions from each of the system's components to the pathophysiology of neuropsychiatric illnesses are briefly discussed, as are the many new pharmacological targets for drug development provided by the system, especially as they pertain to the proceeding preclinical and clinical articles in this issue.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest

Dr. Niciu and Mr. Kelmendi have no potential conflicts to report.

Figures

Figure 1
Figure 1. Glutamatergic Neurotransmission
Due to the risk of excitotoxic damage in the wake of excessive glutamatergic stimulation, precise physiological control of glutamate must be maintained in the mammalian CNS. Glutamine (Gln) is converted to glutamate (Glu) by glutaminase [though glutamate may also be derived from the TCA cycle (not shown)]. Glu is packaged into presynaptic vesicles by vesicular Glu transporter (VGLUT) proteins and synaptically released in an voltage-dependent manner through vesicular interactions with SNARE proteins. Synaptically-released Glu is recycled from the extracellular space by excitatory amino acid transporters (EAATs) expressed predominantly on astroglia. In astrocytes, Glu is converted to Gln by Gln synthetase and exported extracellularly to be taken up again by neurons. Additionally, system x-C is a cystine/glutamate antiporter expressed on glia that also contributes to Glu recycling. Glu receptors are present on presynaptic and postsynaptic neurons as well as on glial cells. These include both ionotropic receptors (NMDA, AMPA/KA) and metabotropic receptors (mGluRs). The effect of Glu is determined by the receptor subtype, localization (synaptic, perisynaptic and extrasynaptic), and interactions with various scaffolding and signaling proteins (not shown) in the postynaptic density. Glu receptor stimulation results not only in rapid ionotropic effects but also synaptic plasticity, e.g. long-term potentiation (LTP) and long-term depression (LTD), via cognate signal transduction cascades.
Figure 2
Figure 2

References

    1. aan het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ. Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry. 2010;67:139–45. - PubMed
    1. Abraham WC. Metaplasticity: tuning synapses and networks for plasticity. Nat Rev Neurosci. 2008;9:387. - PubMed
    1. Alam MR, Johnson RC, Darlington DN, Hand TA, Mains RE, Eipper BA. Kalirin, a cytosolic protein with spectrin-like and GDP/GTP exchange factor-like domains that interacts with peptidylglycine alpha-amidating monooxygenase, an integral membrane peptide-processing enzyme. J Biol Chem. 1997;272:12667–75. - PubMed
    1. Albrecht P, Lewerenz J, Dittmer S, Noack R, Maher P, Methner A. Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a neuroprotective drug target. CNS Neurol Disord Drug Targets. 2010;9:373–82. - PubMed
    1. Alt A, Weiss B, Ogden AM, Knauss JL, Oler J, Ho K, Large TH, Bleakman D. Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. Neuropharmacology. 2004;46:793–806. - PubMed

Publication types